• Kite Unveils Anticipated CAR-T Cancer Data Positive But Not Complete

    Xconomy | Kite Pharma has dipped into a highly anticipated clinical trial of its cancer treatment, KTE-C19, to release a partial set of data. Although not complete, the data bolster the view that Kite could be the first among its peers to win the FDA's green light.

    Sep 27, 2016

  • The Sequencing App and the Quest for Fun

    Bio-IT World | The latest way to get into your genome is a $50 app-based venture that promises to give you a peek into your ancestry and tell you what kinds of bacteria you’re harboring in your mouth. Seeq launched earlier this month offering ultra-low coverage sequencing of the genome, oral microbiome sequencing, and ancestry reports. The goal is an extremely inexpensive infrastructure for people to get a little bit of genomic data and participate in research in a way that’s easy and fun.

    Sep 26, 2016

  • Top Scientists Cautious About Curing Cancer With Immunotherapy

    STAT | There's been a lot of excitement about immunotherapy as a tool to treat cancer. But top experts on Sunday struck an unexpected note of caution.

    Sep 26, 2016

  • New Genomics Pipeline Combines AWS, Local HPC, and Supercomputing

    HPCwire | Declining DNA sequencing costs and the rush to do whole genome sequencing (WGS) of large cohort populations presents an infrastructure challenge that some researchers are solving with a hybrid approach.

    Sep 23, 2016

  • When “Actionable” Genomic Sequencing Results Cannot Be Acted Upon

    JAMA Oncology | Brian J. Zikmund-Fisher recounts an interaction he had with a participant involved in genomic sequencing, in which the term “actionable” led to false hope and dashed expectations.

    Sep 23, 2016

  • Gilead Allergan Seen Trailing Intercept In Ongoing NASH Battle

    Investor's Business Daily | Gilead is trailing Intercept in the battle against NASH, Credit Suisse analyst Alethia Young said Thursday, two days after Botox maker Allergan jumped in.

    Sep 23, 2016

  • Chan Zuckerberg Initiative Lays Out Plan For Funding Disease Research

    Bio-IT World | The Chan Zuckerberg Initiative took to Facebook Live yesterday to lay out their plan of funding the Initiative’s first project. The project, a Biohub located in San Francisco, will combine the knowledge of renowned scientists and engineers in the pursuit of curing disease. 

    Sep 22, 2016

  • Monsanto Licenses CRISPR Technology To Modify Crops

    STAT | Agriculture giant Monsanto has licensed CRISPR-Cas9 genome-editing technology from the Broad Institute to develop modified seeds.

    Sep 22, 2016

  • Getting Exascale Right, Not First

    TOP500 | The path to exascale computing hasn't been an easy one. It has had to face a daunting set of challenges in energy efficiency, application parallelism, and system reliability, just to name a few. The difficulties in bringing the hardware and software up to this level is considerable, but there is a more fundamental challenge at the heart of exascale: doing the necessary work of building an ecosystem that will last for a decade or more, not just for a handful stunt machines.

    Sep 21, 2016

  • Taking Care Of Our Own: HR In The Age Of Genomics

    Bio-IT World | As far as their employees are concerned, who among these life-science players are putting their money where their mouths are? The search has been on at Bio-IT World for those organizations who are taking the logical step of subsidizing the sequencing their own employees' genomes and the clinical interpretation thereof.

    Sep 21, 2016

  • Approving A Muscular Dystrophy Drug Ignites A Civil War At The FDA

    Forbes | Yesterday, the Food and Drug Administration made history, approving a drug to treat Duchenne muscular dystrophy that works by targeting the genetic mutation at the root of the disease. The decision was unique for reasons that were not just scientific.

    Sep 20, 2016

  • Childhood Cancer Targeted By Sanger Institute And St. Jude Children’s Research Hospital Data-Sharing Agreement

    Bio-IT World News Brief | St. Jude's Children's Research Hospital's agreement with the Wellcome Trust Sanger Institute unifies the institute's COSMIC database with the data mining and visualization system of the hospital to better understand the nature of childhood cancers.

    Sep 19, 2016

  • Getting Ready For San Diego: Marking Our Agendas For The Converged IT Summit

    Bio-IT World | The second annual Converged IT Summit covers an impressive list of speakers expanding the realms of infrastructure and data science. The speakers cover a variety of subjects, such as personalized cardiac therapy, IT for life sciences, and much more.

    Sep 19, 2016

  • Oracle is gunning for AWS with new infrastructure offering

    Computerworld | Larry Ellison has a message for Amazon Web Services: Oracle will give Amazon a run for its money in the cloud market.

    Sep 19, 2016

  • DNA Heist That Wasn’t Sparks Data Questions

    Nature News & Comment | Alleged theft from Italian gene bank dismissed - but ownership of samples remains under investigation.

    Sep 16, 2016

  • CRISPR Patent Judges Deny Subpoena For Harvard's George Church

    STAT | The judges hearing a patent dispute over the discovery of CRISPR genome-editing technology denied a request to subpoena Harvard biologist George Church.

    Sep 16, 2016

  • What Makes A Fish Tick? Sequencing The Genome Of The Ocean Sunfish

    Bio-IT World | Researchers at A*STAR, Singapore, and China National Genebank have successfully sequenced the genome of the ocean sunfish. This is a key step in answering questions about what goes into making this mysterious fish so unique.

    Sep 15, 2016

  • Big Plans At The Broad

    Bio-IT World News | Broad Institute’s Bill Mayo is setting lofty goals for the future of the research institute. He’s got big plans for connecting to the Broadies off-sight, machine learning in clinical trials, and upgrading on-sight storage. He’s thoroughly enjoying all of it.

    Sep 14, 2016

  • New Relay Therapeutics Aims Supercomputers, $57M At Protein Motion

    Xconomy | A group of scientists and entrepreneurs believe that computers and various biotechnologies can determine how proteins, instead of folding into a permanent shape, shimmy from one shape to another, and how those back-and-forth states can be exploited to treat disease. They've formed a startup called Relay Therapeutics to test the concept and make drugs for cancer and other diseases.

    Sep 14, 2016

  • Inside Moderna Therapeutics Biotech's Most Secretive Startup

    STAT | Moderna's caustic work environment has driven away top talent. There are signs the secretive startup has hit roadblocks with its most ambitious projects.

    Sep 13, 2016